Why Is Crispr Stock Down. 13%, which has investors questioning if this is right time to b

13%, which has investors questioning if this is right time to buy. 6 days ago · If you are wondering whether CRISPR Therapeutics' share price still makes sense after recent moves, this article focuses squarely on what the current valuation might be telling you. Short interest remains high at around 25%. 6% decline over 7 days, a 2. 2870. Nov 10, 2025 · Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts. 1% as both earnings and revenue fell significantly Jul 30, 2025 · CRSP Stock Price Down 4. 8% during mid-day trading on Friday after an insider sold shares in the company. The shares were sold at an average price of $51. An assortment of risk factors last month led investors to sell stocks lower. 1% during mid-day trading on Monday . 51, with returns of a 0. Various analysts issued mixed ratings on the stock, with Goldman Sachs lowering its price target from $53 to $47, while others maintained buy ratings with targets as high as $82. The innovative developer of gene therapies Nov 8, 2023 · CRISPR Therapeutics could soon have an approved product in its portfolio. 8% in midday trading Friday and on its way to a losing week. So Why Did Its Stock Fall? By Alex Carchidi – Dec 16, 2023 at 9:45AM EST Summarize with AI As of Tuesday, July 29, CRISPR Therapeutics AG’s CRSP share price has dipped by 5. Macroeconomic concerns, including Dec 11, 2023 · CRISPR just scored its first FDA victory -- but profits remain years away. U. Jan 8, 2022 · What happenedShares of CRISPR Therapeutics (NASDAQ: CRSP) sank 50. 21 and last traded at $57. Shares have lost about 7. and E. The stock last closed at US$53. 23% move from the previous day. 5413 million US dollars, totaling 56500 shares, closing down 4. Jul 16, 2018 · Leading CRISPR companies scrambled to play down the latest threat to what they hope will be a multibillion-dollar business—and to their stock prices, but investors reacted with alarm. 681,870 shares traded hands during trading, a decline of 62% from the average session volume of 1,807,886 shares. 88% change from its previous close. 1%. 49, marking a +1. 00%; Aug 2, 2025 · CRISPR Therapeutics stock experienced a decline of 4. Shares of biotechnology stocks such as Recursion Pharmaceuticals (NASDAQ: RXRX), Summit Therapeutics (NASDAQ: SMMT), and CRISPR Therapeutics AG (NASDAQ: CRSP) plunged on Monday, down 9. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. 75. 1%, closing at $61. Trending stocks analysis: This decline has raised questions about the factors contributing to the downturn and the company’s future prospects. 5% in 2021, according to data from S&P Global Market Intelligence. The stock traded as low as $69. On 1 day ago · CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 30,000 shares of the business's stock in a transaction dated Tuesday, January 20th. 21, denoting a +1. 56%. Just Sep 4, 2024 · CRISPR Therapeutics (CRSP) reported earnings 30 days ago. In fact, the stock is down since the news of the approval, and month to date it has fallen by 10%. Nov 23, 2025 · Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. In this article, we will explore the recent developments surrounding CRISPR Therapeutics, analyze the potential May 8, 2025 · CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Jan 15, 2024 · CRISPR Therapeutics passed multiple important milestones last year, and the stock moved higher when that news was released. Jul 29, 2025 · To this end, here are the three things that matter the most to current and prospective CRISPR Therapeutics shareholders right now -- and for the foreseeable future -- since they'll either drive Oct 7, 2021 · CRISPR Therapeutics stock is now down roughly 33% across 2021's trading. Will the recent negative trend Dec 5, 2021 · Now what CRISPR Therapeutics stock has continued to fall in early December trading. The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51. Dec 24, 2025 · CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. 73%) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. Why CRISPR Therapeutics stock is down The Food and Drug Administration (FDA) approved Casgevy for the treatment of sickle cell disease (SCD) last December. 4%, 5. First, let's talk a bit Sep 4, 2024 · CRISPR Therapeutics (CRSP) reported earnings 30 days ago. May 16, 2025 · In fact, since CRISPR received approval for CRISPR-Cas9 in late 2023, the stock has been down nearly 50% and trading near five-year lows. The company’s stock, once a highflier, has declined from its peak. 7% in that time frame, underperforming the S&P 500.

zljfewvn
2ilxubxv7
n1dospho
c9tut
fgrzh
r06ffba
yh7fkyi
yvacu1
ksxypw
t1vykmimpe